Omnicell reported third-quarter 2026 revenue of $308 million, down $3 million, or 1%, from a year earlier, while GAAP net income rose to $11 million, or $0.24 per diluted share, from $5 million, or $0.12. The company raised its full-year 2026 non-GAAP EBITDA and non-GAAP earnings per share guidance, so profit expectations improved even as revenue slipped.
Q3 2026 non-GAAP net income was $27 million, or $0.58 per diluted share, versus $24 million, or $0.51, in Q3 2025.
Full-year 2026 non-GAAP EBITDA guidance was raised to $187 million-$193 million; non-GAAP EPS guidance was raised to $2.48-$2.56.
Full-year 2026 total revenue guidance was tightened to $1.225 billion-$1.231 billion.
As of September 30, 2026, cash and cash equivalents were $315 million and the company had $350 million of undrawn revolving credit availability.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
From Omnicell's 10-Q and 10-K filings (SEC XBRL). YoY compares each quarter with the same quarter a year earlier; it is blank when the year-ago figure is missing or negative.
Annual results
Fiscal year
Revenue
Growth
EPS (diluted)
Growth
Net margin
FY2025
$1.18B
+6.5%
$0.04
-85.2%
0.2%
FY2024
$1.11B
-3.0%
$0.27
—
1.1%
FY2023
$1.15B
-11.5%
$-0.45
-475.0%
-1.8%
FY2022
$1.30B
+14.5%
$0.12
-92.6%
0.4%
FY2021
$1.13B
+26.9%
$1.62
+118.9%
6.9%
Frequently asked questions
When is Omnicell's next earnings date?
Omnicell has not announced a report date within the next three weeks. US companies usually report three to six weeks after each quarter ends; this page updates as soon as the date is on the calendar.
What did Omnicell earn last quarter?
For the quarter ended Sep 2026, Omnicell reported diluted EPS of $0.24 (+100.0% year over year) on revenue of $307.85M (-0.9%).
Where do these numbers come from?
Reported revenue, net income and EPS come from the company's own 10-Q and 10-K filings with the SEC (XBRL data). The report date and consensus estimate come from the Nasdaq earnings calendar.
Not investment advice. Figures can be restated by the company in later filings.